Seattle Genetics, GSK in Next-Generation Antibody Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Seattle Genetics' third deal in two months signals big pharma's growing interest in antibody conjugate technology or "empowered" antibodies for immunotherapies targeting cancer and other hard-to-treat diseases.